MedTrace Logo

A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease

NCT06935929 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 839

Last updated 2025-04-20

No results posted yet for this study

Summary

From January 2020 to January 2025, Crohn's disease (CD) patients and gender- and age-matched normal controls were collected from the Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University. The aim of this research is to explore the associations of microribonucleic acids (miRNAs) gene polymorphisms with the risk and clinicopathological characteristics of CD, and to analyze the effects of miRNAs gene variantions on the clinical response of ustekinumab (UST) treatment in CD patients at week 8.

Conditions

  • Crohn Disease

Interventions

BIOLOGICAL

Ustekinumab - Standard Dosage

Some CD patients received sufficient UST (6 mg/kg) intravenous infusion at week 0, followed by one subcutaneous dose of 90 mg UST at week 8.Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks.

Sponsors & Collaborators

  • Second Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2025-01-01
Completion
2025-01-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06935929 on ClinicalTrials.gov